[1] Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. International Journal of Antimicrobial Agents 2010; 36S: S50–S54.
[2] Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017; 215 Suppl1:S28–36.
[3] Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paule, M. Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy 2013; 57: 5104–5111.
[4] Sharma R, Patel S, Abboud C, Diep J, Ly NS, Pogue JM, Kaye KS, Li J, Rao GG. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. International Journal of Antimicrobial Agents 2017; 49: 224–232.
[5] Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, Pancholi P. Synergy Testing by Etest, Microdilution Checkerboard, and Time-Kill Methods for Pan-Drug-Resistant a Acinetobacter baumannii. Antimicrobial agents and chemotherapy 2010; 54: 4678–4683.
[6] Pankey GA, Ashcraft DS, Dornelles A. Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagnostic Microbiology and Infectious Disease 2013; 77: 220-226.
[7] Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis 2004; 39:55-60.
[8] Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, Pignatari AC, Tufik S. Rapid detection and identification of Metallo-beta-lactamase encoding genes by multiplex real time PCR assay and melt curve analysis. J. Clin. Microbiol 2007; 2: 544–547.
[9] Mostachio AK, Van der Heidjen I, Rossi F, Levin AS, Costa SF. Multiplex PCR for rapid detection of genes encoding Oxacillinases and metallo-beta-lactamases in colistin-susceptible Acinetobacter spp. J. Med. Microbio 2009; 58:1522–4.
[10] Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014; 30: 2068–2069.
[11] Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. Multilocus Sequence Typing of Total Genome Sequenced Bacteria. J. Clin. Microbiol 2012; 50: 1355-1361.
[12] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (M100-S28). Wayne (PA): CLSI; 2018.
[13] European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1; 2018. Available from: http://www.eucast.org/. [Accessed 10 October 2018].
[14] Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J. Antimicrob. Chemother 2006; 57: 573–576.
[15] Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005. p. 365–440.
[16] García-Salguero C, Rodríguez-Avial I, Picazo JJ, Culebras E. Can plazomicin alone or in combination be a therapeutic option against carbapenem resistant Acinetobacter baumannii? Antimicrob.Agents.Chemother 2015; 59: 5959 –5966.
[17] Pankey GA, Ashcraft DS. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob. Agents. Chemother 2005; 49: 2959–64.
[18] Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
[19] Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis 2012; 31: 695–701.
[20] Evren E, Azap OK, Çolakoğlu S, Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48–positive Klebsiella pneumoniae strains. Diagnostic Microbiology and Infectious Disease 2013; 76: 335–338.
[21] Singkham-in U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Diagnostic Microbiology and Infectious Disease 2018; 91: 169–17.
[22] Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J. Antimicrob. Chemother 2014; 69:1856–1865.
[23] Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M, Vay C, Famiglietti A. Activity of the colistin–rifampicin combination against colistin-resistant, carbapenemase producing Gram-negative bacteria. Journal of Chemotherapy 2014; 26: 211-216.
[24] Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis. International Journal of Antimicrobial Agents 2015; 45: 8–18.
[25] Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, Kim SH, Lee SO, Choi SH, Woo JH, Kim YS, Chong YP. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2016; 60: 6774–6779.
[26] Brennan-Krohn T, Pironti A, Kirby JE. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018; 62: e00873-18.
[27] Ostenson RC, Fields BT, Nolan CM. Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother 1977; 12: 655–9.
[28] Montanari MP, Piccolib I, Mingoiaa M, Marchettib F, Varaldoa PE. Synergistic potential of ceftazidime plus amikacin or levofloxacin against Pseudomonas aeruginosa as determined using a checkerboard and a disk diffusion technique. Diagnostic Microbiology and Infectious Disease 2005; 53: 157–160.
[29] Stein C, Makarewicz O, Bohnert, JA, Pfeifer Y, Kesselmeier M, Hagel S, Pletz MW. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug- Resistant Clinical Klebsiella pneumonia Isolates. PLoSONE 2015: 10(6): e0126479.
[30] Chachanidze V, Curbelo-Irizarry A, Ashcraft D, Pankey G. In vitro synergy of levofloxacin plus piperacillin-tazobactam against Pseudomonas aeruginosa. Interdiscip. Perspect. Infect. Dis 2009; 984934.
[31] Pankey GA, Ashcraft, DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest® and time-kill assay. Diagnostic Microbiology and Infectious Disease 2009; 63: 228–232.
[32] Pankey GA, Ashcraft, DS. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Disease 2011; 70: 561–564.
[33] Sakoulas G, Olson J, Yim J, Singh NB, Kumaraswamy M, Quach DT, Rybak MJ,Pogliano J, Nizet V. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2016;60(11):6609-6618.
[34] Brochmann RP, Helmfrid A, Jana B, Magnowska Z, Guardabassi L. Antimicrobial synergy between carprofen and doxycycline against methicillin-resistant Staphylococcus pseudintermedius ST71. BMC Vet Res. 2016; 12(1):126.
[35] Sy CL, Huang TS, Chen CS, Chen YS, Tsai HC, Wann SR, Wu KS, Chen JK, Lee SS,Liu YC. Synergy of β-Lactams with Vancomycin against Methicillin-Resistant Staphylococcus aureus: Correlation of Disk Diffusion and Checkerboard Methods. J Clin Microbiol 2016; 54(3):565-8.
[36] Silva FM, Carmo MS, Silbert S, Gales AC. SPM-1-producing Pseudomonas aeruginosa: analysis of the ancestor relationship using multilocus sequence typing, pulsed-field gel electrophoresis, and automated ribotyping. Microb Drug Resist 2011; 17:215– 220.
[37] Chagas TP, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef AP, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008–2011): countrywide spread of OXA-23–producing clones (CC15 and CC79). Diagnostic Microbiology and Infectious Disease 2014; 79: 468–472.
[38] Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microbial Genomics 2019.